OncoMed: Annual Report 2015 (OncoMed) - Mar 12, 2016 - Anticipated expiry of patents in US and ex-US related to composition of matter and methods of use in 2031; Anticipated expiry of composition of matter patent in US in 2034; Anticipated expiry of patents in US related to certain Fzd-Fc biologics and uses of Fzd-Fc biologics in the treatment of cancer 2026 or 2027; Anticipated expiry of patents in US related to polynucleotides in 2026; Anticipated expiry of patents US, PCT and ex-US related to ipafricept, certain uses of ipafricept and/or related biomarkers between 2026 and 2036
Anticipated patent expiry • Oncology
|